Drug Patent Expirations for May 4, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

REBETOL (ribavirin)
Merck Sharp Dohme
Patent number:6,177,074
Expiration Date:May 1, 2017

REBETOL (ribavirin)
Merck Sharp Dohme
Patent number:6,461,605
Expiration Date:May 1, 2017

REBETOL (ribavirin)
Merck Sharp Dohme
Patent number:6,524,570
Expiration Date:May 1, 2017

REBETOL (ribavirin)
Schering
Patent number:6,177,074
Expiration Date:May 1, 2017

REBETOL (ribavirin)
Schering
Patent number:6,461,605
Expiration Date:May 1, 2017

REBETOL (ribavirin)
Schering
Patent number:6,524,570
Expiration Date:May 1, 2017

VIVITROL (naltrexone)
Alkermes
Patent number:5,792,477
Expiration Date:May 2, 2017

VIVITROL (naltrexone)
Alkermes
Patent number:5,916,598
Expiration Date:May 2, 2017

VIVITROL (naltrexone)
Alkermes
Patent number:6,403,114
Expiration Date:May 2, 2017

IRESSA (gefitinib)
Astrazeneca Pharms
Patent number:5,770,599
Expiration Date:May 5, 2017

IRESSA (gefitinib)
Astrazeneca
Patent number:5,770,599
Expiration Date:May 5, 2017

ALINIA (nitazoxanide)
Romark
Patent number:5,968,961
Expiration Date:May 7, 2017

ALINIA (nitazoxanide)
Romark
Patent number:6,117,894
Expiration Date:May 7, 2017

DrugPatentWatch provides instant access to actionable insights on pharmaceutical drugs.

For more information try a trial


Comments are closed.

Do NOT follow this link or you will be banned from the site!
%d bloggers like this: